

DISTRICT COURT OF QUEENSLAND

REGISTRY: BRISBANE

NUMBER: 1707/18

Plaintiff: **MICHAEL HONSUE CHO**

AND

Defendant: **MARK THOMAS**

AFFIDAVIT

MICHAEL HONSUE CHO of 11 Station Street, Kew East, in the State of Victoria, inventor and company director, states on oath:

1. I am the plaintiff in the present proceeding.

Background and family

2. I was born in Canton, China, on 16 March 1966. I lived eleven years in China before I moved to Australia. I have lived in Australia since 1977, but from 2003 I have spent more than six months outside Australia each year. I understand and participate in both western and Chinese culture. I have friends and personal and business acquaintances in both China and Australia (including in Queensland).
3. I go by both the name "Michael Honsue Cho" and the name "Honsue Cho". The first of these is the name by which I am primarily known in Australia, and the second is the name by which I am primarily known in China. However, this distinction is not absolute. I have observed that there are people in Australia who

Signed: 

AFFIDAVIT

Filed on behalf of the Plaintiff

Form 46, Version 1

Uniform Civil Procedure Rules 1999

Rule 431

Taken By: 

Jones Day

Level 31 Riverside Centre

123 Eagle Street

Brisbane QLD 4000

Tel: 07 3085 7000

Fax: 07 3085 7099

know me as and refer to me as “Honsue Cho” and people in China who know me as and refer to me as “Michael Honsue Cho”.

4. I have been married to my wife Wendy Cho since 1999. We have two children: a son named Remy Cho currently aged 18, and a daughter named Martelle Cho who is presently 17 years’ old. Remy currently plays football professionally for the Leganes football (soccer) team in Spain as part of the La Liga competition (the same competition in which Real Madrid, for example, competes). He is the first person of Chinese descent to play for a La Liga team. Before signing with Leganes, he played in the Victorian State football team. Martelle attends the John Cranko Ballett Schule (that is, ballet school) in Stuttgart on a full scholarship. She has performed in the Australian Conservatoire of Ballet productions “Swan Lake” and “The Nutcracker”.
5. I also have two sisters named Anne Sia and Diana Soo and two brothers, Hon Hong Cho and Alan Hong Len Cho – all four of whom have worked with me in business as set out below.
6. I am very proud of and close to my family, and their opinion of me is enormously important to me.

History as inventor and businessman

7. I have a longstanding history as both an inventor and a businessman.
8. I hold a Bachelor of Science qualification from La Trobe University. I have also undertaken additional post-graduate studies in computer engineering at RMIT University.
9. In my final year of university in 1988, I founded a business selling personal computers: Dolphin Computer, now called Dolphin-iT. My sister joined me in the running of this business shortly after it began operating, and shortly afterwards one of my brothers did too. My other brother joined the business at a later date. The

Signed:

Honsue Cho

Taken By:

A.M. Minto

business employed its first employee, Alice Woon, in around 1989 or 1990. Ms Woon is still an employee of the business today.

10. I became involved in other businesses after 2003, when I began spending part of the year in China (albeit I retain a residence in Australia and spend significant time here each year). I participated, as an investor, in an aluminium extract business. I also worked with a Queensland-based company (now group of companies), Euclidean, and led its expansion into China and Asia. I am still a director of Euclidean China, part of the Euclidean group of companies.
11. I also began inventing while in China, and have done so continuously since then. Many of my projects I still plan to patent and therefore I do not wish to put into the public domain any information about them, as my doing so would prejudice the ability to obtain a patent. A project that I have already patented is an oak wine barrel that differs from conventional wine barrels in that the inner part of the barrel (which is the part that imparts flavour to the wine but, over several years of use, gradually loses its inherent flavour and thus its capacity to impart flavour) can be replaced while the remainder of the barrel remains in use and does not need to be replaced. Despite what is set forth in one of the defamatory articles that is the subject of the present litigation, the technology works as intended and my reason for not seeking to commercialize it is my involvement with other projects.
12. In particular, I have a passion for the life sciences, and technology aimed at treating disease and improving longevity and quality of life. I hope to use my skills in this area for the betterment of humanity. The particular technologies that I discuss below, if they succeed in delivering their intended effects, could revolutionize human health.

Cho Group Limited, Photosoft and NGPDT

13. My patented inventions in connection with the life sciences include a photosensitizing gel by the name of "PhotosoftE4" or "Photosoft" (for which a patent has been granted in Australia, Japan and Singapore). The gel contains a

Signed:



Taken By:



chlorophyll-based chemical called chlorin e4 sodium. The gel may be taken orally or applied directly to skin. Photosoft has no effect until activated by light of a particular frequency.

14. A patent is pending for another of my inventions, "Next Generation Photodynamic Therapy" (NGPDT). NGPDT is a light bed that administers light at a particular wavelength and thereby activates Photosoft. Once activated, Photosoft seeks out and destroys cancerous cells, while triggering the immunity system and leaving healthy cells unharmed.
15. I am the founder of the company Cho Group Limited, as well as being its chairman and major shareholder. The Photosoft and NGPDT technologies are produced and marketed by RMW Cho Group Pty Limited, a related company of Cho Group Limited. I am also the chairman of RMW Cho Group Pty Limited.
16. The Hudson Institute of Medical Research (an affiliate of Monash Health and Monash University) is working with RMW Cho Group Pty Limited and Cho Group Limited in testing the technology.
17. Photosoft and NGPDT both are experimental cancer treatments. I am aware that they have been presented to both prospective customers and investors as such.
18. The technology was tested at a lower dosage on animals, and then on eighty human subjects in 2012. All people who participated in this first test were required to sign a form acknowledging the experimental nature of the technology. An unsigned copy of the form presented to each participant in the first test is exhibited to this affidavit and marked "MHC-1". These initial tests focussed on prostate cancer. The test results were very good, with the treatment consistently destroying cancer cells. The cells did not return or develop any resistance, and there were no side-effects.
19. Since conducting those initial tests, the dosage has been raised. Since the increase in dosage, the testing process has recommenced, with tests being run first on mice. Tests on human subjects have not yet commenced. These tests focus on ovarian

Signed:

Hon Sue Cho

Taken By:

A. McMurdo

cancer. The tests on mice replicate the strong results of the earlier prostate cancer tests.

20. A small number of treatments have been performed in China. The availability of these treatments has not been advertised save through the Cho Group website, and interested parties have approached the business directly. These treatments have been performed at a low dosage, and have successfully treated a range of cancers. All participants in the treatments have been required to sign a form acknowledging the experimental nature of the technology. The form is in English and a copy of form, with a patient's details redacted, is exhibited to this affidavit and marked "MHC-2".
21. As the chairman of Cho Group Limited, and somebody intimately involved in running the business, I am (and at all times have been) aware of how its products, including products delivered through related companies, are marketed to prospective customers and investors. If the NGPDT and Photosoft technologies had been represented as a sure cure for cancer, or as anything other than an experimental treatment, I would be aware of that fact. I am not aware of the technologies being advertised or represented as such, and can say with confidence that they have not been.

Charity work

22. Every year I support a number of charity events.
23. These include the charity event for the EasternHealth Foundation, which I initiated in 2017. The event raises funds for four hospitals in Australia.
24. The events also include the Merdeka Day Ball Charity Ball. This ball is held once a year, and the proceeds are used to help educate children who cannot afford to go to school; the International Chef Charity Gala, the proceeds of which assist patients who cannot afford medical treatment for diseases, with the balance of the proceeds being directly transferred to hospitals.

Henric Cho

A. McMurdo

Signed:

Taken By:

The defamatory articles

25. I became aware of the first of three articles authored by the defendant and published on the uSpiked website www.uspiked.com, and which are pleaded in the amended statement of claim, when a former patient who had been treated with the Photosoft technology in China brought it to my attention.
26. I instructed my lawyers, led by Brett Heading of Jones Day, to draft a letter to the controllers of the uSpiked website requiring that the article be taken down immediately.
27. I reviewed and approved the letter before it was sent. My lawyers advised me that it was sent on 19 May 2017. I believe this to be true, because a copy of the letter was later reproduced in the second defamatory article. My lawyers provided me with a copy of the letter as sent, a copy of which is exhibited to this affidavit and marked "MHC-3". The letter as sent is consistent with the letter I reviewed and approved.
28. From this point in time, I monitored the uSpiked website. I therefore became aware of the publication of the second and third articles shortly after their publication occurred, from my direct observation of the website.
29. I have reviewed the three articles annexed to the amended statement of claim in the present proceeding. I confirm that they correspond to my recollection of the three defamatory articles that I viewed on the uSpiked website at or shortly after the time of their publication.

Discussions with other people

30. In all, approximately twenty people have mentioned the articles (or one or more of them) to me.
31. As well as the patient who first brought the articles to my attention, people who have mentioned the articles to me include the following (all of whom knew me before the articles' publication): Michael Lee (CEO of A1 Team Financial

Signed:

Stan Pui Cho

Taken By:

A. McMurdo

Company in Melbourne), Esmond Wong (owner of the famous restaurants Laksa King in Melbourne), Quoi Quach (owner of Clarendon Hotel and Restaurant Bar in South Melbourne), Elias Chahoud (Head Manager of Dolphin-iT, the business founded by me and mentioned above), my sister, and my brother Hon Hong Cho.

Reaction to the defamatory articles

32. My reaction to each of the three articles was substantially similar. I did or do not distinguish between them depending on whether they use my name, as it was and is clear to me that each of them is about me.
33. It was and is also clear to me that other people would identify me from the articles, and identify me as bound up with the behaviour alleged in the articles. I assumed this to be so because my surname forms the most distinctive part of Cho Group Pty Limited's company name; a large number of the people who access the web pages in question would be brought there by searching for my name in online search engines such as Google or Bing, given that the articles or some of them appear prominently in such search results; significant materials are available online identifying me with the Cho Group Pty Limited, such that any person who read the articles and was sufficiently interested could swiftly identify me using those materials; and from 20 May 2017 (six days after the date carried by the first of the three articles), the same website and the same author published the second article, in which I am identified by name.
34. The meaning I took from the first article, and assumed that other readers of it would take from it also, was that I was a party to misrepresenting to consumers and investors the NGPDT and Photosoft technologies as guaranteed cancer cures, and that I had engaged in this conduct with a view to profiteering from the misfortune of cancer sufferers.
35. I took the same meaning from the second and third articles, and assumed that other readers would too.

Signed:

Hon Sue Cho

Taken By:

A. McMurdo

36. I was deeply shaken by each of the articles. Each of them left me feeling devastated, because they conveyed that I was using my skills and craft as an inventor predatorily, and that I viewed cancer patients as nothing but “cash cows” to be milked for money with no regard for their health or welfare. This was particularly upsetting to me because I knew it to be false and in fact the diametric opposite of the true position and my true motives.
37. The ongoing presence of the articles online, and my inability until now to address them or remedy the situation, fills me with a sense of shame. I feel that I will have lost face, particularly among my Chinese friends and acquaintances. My experience with Chinese culture, based upon my lifelong immersion in it, is that I will be diminished in the eyes of my Chinese friends and acquaintances for as long as the insults contained in each of the three articles remain available online.
38. I have barely been able to stop thinking about the articles since their publication. The fact that the articles are available online and could be read at any moment by any of my friends, personal acquaintances or business acquaintances casts a shadow over almost every social interaction that I have. It is constantly in my mind that the person I am speaking to at any given time could have read the articles, and could have formed a fundamentally false perception of me as a result.

Prominence of the defamatory articles in internet search results

39. In this regard, I have performed web searches on what I believe to be the two most popular search engines, Google and Bing. In the case of both search engines, I have caused the expressions “Michael Honsue Cho” and “Honsue Cho” to be used (alternatively to each other) as the search terms. I have caused these searches to be run with my location set to Australia (in the case of Google and Bing), China (in the case of Bing) and Hong Kong (in the case of Google as China is not offered as an option in the search settings on Google), to control for any differences that might be seen by a person running the search based upon their geographic location. The results are exhibited to this affidavit and marked “MHC-4”.

Signed:

Hon Sue Cho

Taken By:

A. McMurdo

40. In each case, certain of the articles are among the highest-ranking search results and therefore among the first results seen by a person searching for me using Google or Bing in Australia or Hong Kong. They are seen before material that is more representative of my life and achievements as an inventor and in business.

Failure of the defendant to remove the articles

41. Despite the request contained in the letter reproduced as MHC-3, the defendant has not at any stage removed the articles, communicated any intention to remove them, withdrawn the allegations contained in the articles, or apologized for them.

Identity of the defendant

42. I have also observed a Twitter account maintained under the username "Mark Thomas" (with the login name @MarkCTN, and accessible at the web address <http://www.twitter.com/markctn>). This account lists www.uspiked.com as the user's website, and provides the following user description: "Investigative & Advocacy Journalist. Impact-driven Journalism for the public. Editor-in-Chief @uspiked". The account has been active since August 2009, and contains links to each of the three articles contemporaneous with their date of publication. It also focuses on journalism and the politics of South Africa (where I now know the defendant to have been based at the material time). I have also observed that the Twitter account @uspiked, the feed of which appears on the www.uspiked.com website, lists the @MarkCTN account as an account that it "follows", and has commented upon Twitter posts by @MarkCTN.
43. Based upon these matters, I believe the @MarkCTN account to be maintained by the same Mark Thomas who is the defendant in the present proceeding and who is the author of the articles.

Signed:

Hon Sui Cho

Taken By: *A. McMurdo*


44. On this basis, I further believe that the defendant is the editor-in-chief of uSpiked as averred in the user information for @MarkCTN, and that as such he exercises control over its editorial decisions. I therefore note that uSpiked, too, has not removed the articles, communicated any intention to remove them, withdrawn the allegations contained in the articles, or apologized for them.

General

45. All the facts and circumstances above deposed to are within my own knowledge save such as are deposed to from information only and my means of knowledge and sources of information appear in this my affidavit.

SWORN by Michael Honsue Cho on 14 March 2019 at Melbourne, in the State of Victoria, in the presence of:

Deponent



Solicitor/~~Barrister~~/Justice of the
Peace/~~Commissioner~~ for Declarations

Alexandra Marie McMurdo
Solicitor

DISTRICT COURT OF QUEENSLAND

REGISTRY: BRISBANE

NUMBER: 1707/18

Plaintiff: **MICHAEL HONSUE CHO**

AND

Defendant: **MARK THOMAS**

CERTIFICATE OF EXHIBITS

Bound and marked "MHC-1" to "MHC-4" are the exhibits to the affidavit of MICHAEL HONSUE CHO sworn on 14 March 2019.



Deponent



Taken by

Alexandra Marie McMurdo
Solicitor

CERTIFICATE OF EXHIBITS

Filed on Behalf of the Plaintiff
Form 47, Version 2
Uniform Civil Procedure Rules 1999
Rule 435
AUI-930575758v1

Jones Day
Level 31, Riverside Centre
123 Eagle Street, Brisbane, Qld, 4000
Tel: 07 3085 7000
Fax: 07 3085 7099

DISTRICT COURT OF QUEENSLAND

REGISTRY: BRISBANE

NUMBER: 1707/18

Plaintiff: **MICHAEL HONSUE CHO**

AND

Defendant: **MARK THOMAS**

LIST OF EXHIBITS

Exhibit	Document	Pages
MHC-1	Unsigned copy of form presented to each participant in first test	1-5
MHC-2	Redacted form presented to participants in China	6-10
MHC-3	Correspondence from Jones Day to uSpiked, dated 19 May 2017	11-13
MHC-4	Bing and Google searches, dated 14 March 2019	14-28

LIST OF EXHIBITS

Filed on Behalf of the Plaintiff
Form 47, Version 2
Uniform Civil Procedure Rules 1999
Rule 435

Jones Day

Address: Level 31, Riverside Centre
123 Eagle Street, Brisbane, Qld, 4000
Tel: 07 3085 7000
Fax: 07 3085 7099

Protocol

To Assess the Effect of Sono-Photo Dynamic Therapy (SPDT) on men with localised prostate cancer.

Principal Researcher: Mr Donald L Murphy

Associate Researchers: Professor Avni Sali, Dr Brian Meade

1. Introduction

Participants to be invited to take part in this research project will be men who are being treated for localised prostate cancer. This research project is a single arm, prospective pilot study, to see whether the novel use of existing SPDT treatment methods, can improve the clinical outcome of men with localised prostate cancer.

This document explains the proposed protocol and details the procedures to be performed. Knowing what is involved will help the potential patient decide if he wants to take part in this research. Please read this information carefully. Ask questions about anything that you do not understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or healthcare worker.

Participation in this research is voluntary. If you do not wish to take part, you do not have to. You will receive the best possible continuing care, whether you take part or not.

If you decide that you wish to take part in the research project, you will be asked to read and sign the consent section. By signing it you are telling us that you:

- *Understand what you have read
- *Consent to take part in the research project
- *Consent to participate in the research processes that are described
- *Consent to the use of your personal and health information as described
- *Consent to paying the costs of this treatment.

2. What is the purpose of this research project?

The purpose of this pilot study is to determine if Sono-Photo Dynamic Therapy (SPDT) can have a positive therapeutic clinical effect on the cancer cells, in localised prostate cancer. The therapy has been used successfully in other medical conditions and in men with advanced prostate cancer with these reports being favourable.

SPDT has not however been tried, in men with localised prostate cancer. This research project addresses that question.

- * Certain chemical agents (sensitisers) react to specific wavelengths or frequencies of light and sound and in the process a high-energy, toxic form of oxygen is produced.
- * Cancer cells which have selectively retained and aggregated these agents undergo cell death and/or subsequent apoptosis as a result of the SPDT process.
- * The treatments performed in the medical imaging department and/or the doctor's rooms under medical supervision, have minimal side effects and can be repeated.
- * This study has not been done before and may lead to significant progress in prostate cancer management.
- *This is a single arm, prospective pilot study.
- * Subsequent research on this topic will be designed, depending on the results of this project.
- * This project is being conducted by the above named researchers.
- * This project is part of our academic research programme and has no external funding.
- * There will be three cycles of this treatment over 10 weeks.

3. What does participation in this research project involve?

Participation in this research project involves the following procedures:

- A. Before treatment, the patient will undergo a relevant clinical history and examination session. A urinary flow study, together with standard cancer tests, involving blood tests and medical imaging scans will be performed / or reviewed.
- B. A urine sample will be collected before and after the completion of treatment. This is to see whether certain volatile compounds are able to be detected before the SPDT, but disappear after treatment. This is a potential biomarker, to monitor prostate cancer treatment progress.
- C. The patient will be given sensitiser agents to take orally in droplet form. Agent washout occurs from normal tissues over the ensuing day, while accumulation and retention occurs in cancer cells.
- D. The patient will be treated with ultrasound and light to the prostate on the following day.

The ultrasound will be applied in two ways as separate lower abdominal and perineal procedures, each directed at the prostate gland with no significant discomfort or anticipated side effects.

In the afternoon the patient will return for the light treatment when under sterile conditions and local anaesthetic gel, a laser probe, emitting red light will be inserted to the level of the prostate gland, through a catheter placed in the urethra. The method of the passage of this catheter is a standard medical / urological procedure. This light will activate the photosensitive chemical agent retained in the prostate gland cancer cells. It is anticipated that the participant will have a spontaneous return to normal urination after each of these treatments, with supervision to this effect.

Trans-rectal laser red light illumination of the posterior prostate gland will also be performed, a procedure similar to that performed during the trans-rectal ultrasound study, previously experienced by the patient. The light energy source will be applied for a maximum of 30 minutes.

When available at the National Institute of Integrative Medicine Clinic, Hawthorn, whole body light bed therapy may be utilized under medical supervision, as further light therapy.

Eye protection will be provided during treatment.

Your comfort will be managed by the medical team.

Three months after the SPDT, patients will return for history and examination review. Follow up blood and urine tests to assess the treatment impact on the cancer cells will be performed.

4. What will happen to urine samples?

The collected urine will be stored as frozen samples until both pre-treatment and post-treatment samples have been collected, and then they will be transported for group testing for volatile substances at the laboratory. The frozen storage repository will be under the control of Mr Donald Murphy.

* The specimens will be disposed of according to national health standards, at the completion of the study.

* This research project does not involve the establishment of a tissue bank.

5. What are the possible benefits?

We cannot guarantee or promise that the participant will receive any direct benefits from this research; however, possible benefits may include a greater understanding and knowledge regarding prostate cancer. The SPDT also holds out the possibility of being therapeutic for your prostate cancer, as PDT has been shown to kill cancer cells.

6. What are the possible risks?

There are no directly recognizable risks by taking part in this study. There may be discomfort associated with the internal treatments. The unlikelihood of urinary voiding difficulties and urethral symptoms will be appropriately managed. Exposure to natural sunlight is not recognized as a problem with the second generation chemical sensitizer used in/during this study but standard light precautions will however be advised.

7. Can other treatments be taken during this research project?

It is important that the participant tells the doctor and the research staff about any treatments or medications being taken, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments. You should also tell your doctor about any changes to these treatments during your participation in the research.

8. Do I have to take part in this research project?

Participation in any research project is voluntary. If you do not wish to take part you do not have to. If you decide to take part and later change your mind, you are free to withdraw from the project at any stage. Your decision whether to take part or not to take part, or to take part and then withdraw, will not affect your routine treatment OR your relationship with those treating you.

9. What if I withdraw from this research project?

If you decide to withdraw, please notify a member of the research team before you withdraw. This notice will allow that person or the research supervisor to inform you if there are any health risks or special requirements linked to withdrawing. Any urine samples already provided will be disposed of according to national health standards.

10. Could this research project be stopped unexpectedly?

You will be advised if the project is to be terminated before completion and the reasons that might make termination necessary.

11. How will I be informed of the results of this research project?

You will be provided with a summary of the results, when the research project is completed.

12. What else do I need to know and what will happen to information about me?

Any information obtained in connection with this research project that can identify you will remain confidential and will only be used for the purpose of this research project. It will only be disclosed with your permission, except as required by law.

Information about you may be obtained from your health records held at this and other, health services for the purposes of this research.

In any publication and/or presentation, information will be provided in such a way that the participants cannot be identified.

13. How can I access my information?

In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right to access the information collected and stored by the researchers about you. You also have the right to request that any information, with which you disagree, be corrected. Please contact one of the researchers named at the end of this document if you would like to access your information.

14. Is this research project approved?

The Human Research and Ethics Committee of the National Institute of Integrative Medicine have approved the ethical aspects of this research project. This project will be carried out according to the National Statement on Ethical Conduct in Human Research (2007) produced by the National Health and Medical Research Council of Australia.

The information in this document has been developed to protect the interests of the people who have agreed to participate in this human research study.

15. The sensitisers used in this trial, which are currently used internationally, are not Australian TGA approved and are being used for your specific individual treatment as per this trial, with your informed consent.

16. Consent.

I have read, in a language that I understand, this document and I understand the purposes, procedures and risks of this research project as described within it. I give permission for my doctors, other health professionals, hospitals or laboratories outside this hospital to release information to Mr Donald Murphy concerning my prostate cancer disease and the treatment that is needed for this project. I understand that such information will remain confidential.

I have had an opportunity to ask questions and I am satisfied with the answers I have received. I freely agree to participate in this research project as described. I understand that I will be given a signed copy of this document to keep.

Participant's name (printed): _____
Signature: _____
Date: _____

Name of witness to participant signature (printed): _____
Signature: _____
Date: _____

Declaration by researcher: I have given a verbal explanation of the research project, its procedures and risks and I believe that the participant has understood that explanation.

Researcher's name (printed): _____
Signature: _____
Date: _____

I consent to the storage and use of the urine samples provided by me, for use in this specific research project as described in Section 4 of this document by Mr Donald Murphy

Participant's name (printed): _____
Signature: _____
Date: _____

Name of witness to participant signature (printed): _____
Signature: _____
Date: _____

Researcher's name (printed): _____
Signature: _____
Date: _____

Note: All parties signing the consent section must date their own signature

17. Whom can I contact?

Whom you may need to contact will depend on the nature of your query, therefore, please note the following: If you want any further information concerning this project or if you have any medical problems which may be related to your involvement in the project (for example, any side effects), you can contact the principal researcher

Name: Mr Donald Murphy

Role: Principal Researcher

Telephone: 0352224844

For complaints:

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Name: Kate Jones

Position: Member, Human Research Ethics Committee, NIIM.

Telephone: 0398040646

A senior member of the research team must provide the explanation and provision of information concerning the research project.

You will be given a copy of this Participant Information and Consent Form to keep.



== Patient's Endorsement ==



Patient's Endorsement

Name	Age	Treatment
Gender	Diagnosis	Period
Body condition before treatment		
<p>I Please note that the following concerning NGPDT treatment:</p> <ol style="list-style-type: none">1. <i>The Hospital</i> does not guarantee that therapy will cure the disease of the patient.2. Several courses of treatment might be required depending upon the condition of the patient, the extent and type of disease as well as their response to treatment.3. While this form of PDT has been shown to be effective in many types of cancer, <i>The Hospital</i> does not guarantee that this therapy will cure your disease. <p>Length of treatment period will depend on patients' condition and severity of disease.</p> <p>This therapy is effective in many cancers but a cure is not guaranteed or implied.</p> <p>II Please give thorough consideration on whether to take our treatment or not. Read all data on the subject that is available, so as to be well informed prior to your decision. Any further questions opinions or clarifications will be promptly provided.</p>		



I understand the NG PDT therapy does not include expenses that may be required for the treatment of other medical conditions. If a patient requires extra hospital care for any other medical or unforeseen expenses; the patient will be required to pay for these other extra medical expenses directly to the hospital. A 5,000 RMB deposit is essential for any patient staying in the hospital. If expenses exceed the 5,000 RMB a patient is required to pay any additional balance. I understand NGPDT is not responsible in any way for the payment of other medical expenses and the Hospital will not loan or pay for any of these expenses. I understand I should have extra funds on hand in case other medical expenses are incurred.

Please choose one of the following options with a "✓"

- ☒ Accept Treatment
☐ Do not accept treatment

Patient's signature _____

Patient's family member's signature: _____

Date: _____

Date: _____



NGPDT Informed Consent Form

I acknowledge the following:

That I have carefully read the information and documentation provided to me about Next Generation Photodynamic Therapy (PDT).

That I have evaluated the risks and possible side effects as a consequence of undergoing PDT and agree to personally bear these risks. If I am uncertain about any aspect of the Therapy, I acknowledge that I can obtain further clarification from The NGPDT treatment centre.

That I have reviewed and carefully considered various cancer treatments, including surgery, chemotherapy, radiotherapy, hormonal therapy and immunotherapy as well as PDT and I have made my decision to pursue PDT myself, free of any outside influence.

That I understand that PDT is new and developing cancer treatment for the 21st Century.

That I understand that NGPDT treatment is not refundable or transferable once the treatment has started.

We take no responsibility for any vision or eye problems associated with NGPDT treatment or any visual problems there after NGPDT treatment. We take special precautionary care by providing special filtered glasses be worn during treatment.

That if I am female, I must avoid pregnancy whilst receiving the PDT, as any failure to do so, may cause serious birth defects or death to a fetus.

MEDICAL DISCLOSURE & CONSENT FORM

I acknowledge that The Hospital does not warrant or represent that PDT is a cure for cancer or that it will be successful or provide any benefit whatsoever and to the extent permitted by law, the Hospital cannot be held liable for any injury, side effect, loss or damage incurred as a result of receiving PDT or from reliance on the information provided by The Hospital, whether arising from strict liability, negligence or otherwise.

I consent to participate in the PDT treatment, to allow collection of my health information for record keeping, I agree to allow other medical institutions or doctors outside NGPDT to



广州友好医院 肿瘤科

Guangzhou Friendship Hospital (Guangzhōu Yǒuhào) Oncology Department

inspect this medical information including medical history symptom, treatment data, etc. The purpose of sharing this information is to improve this combined NGPDT therapy for the benefit of patients.

I acknowledge that I have read and understand the information contained in this form as well as the other documentation provided to me, which includes information about PDT and exclusion criteria for PDT.

PATIENT SIGNATURE :

NAME :

DATE :

NGPDT - Chief Medical Officer :

SIGNATURE :

NAME :

DATE :

YOUHAO DOCTOR:

SIGNATURE :

NAME :

DATE :

Heading, Brett

From: Brett Heading
Sent: Friday, 19 May 2017 2:35 PM
To: info@uspiked.com; ombudsman@uspiked.com
Subject: The Cho Group Ltd and RMW Cho Group Pty Ltd - Publication of Defamatory Material
Attachments: 930234480_1.docx

Mr Thomas

I attach a letter for your urgent attention.

Yours faithfully

Brett Heading (b10)
Partner
JONES DAY® - One Firm Worldwide™
Level 28
Waterfront Place
1 Eagle Street
Brisbane QLD 4000 AUSTRALIA
Office +61 7 3085 7020
Mobile +61 409 608 966
bheading@jonesday.com

(See attached file: 930234480_1.docx)

=====

This e-mail (including any attachments) may contain information that is private, confidential, or protected by attorney-client or other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail, so that our records can be corrected.

=====

JONES DAY

WATERFRONT PLACE • LEVEL 28, 1 EAGLE STREET • BRISBANE QLD 4000

TELEPHONE: +61 7 3085 7000 • FACSIMILE: +61 7 3085 7099

19 May 2017

Partner
Brett Heading
Telephone: +61 7 3085 7020
Email: bheading@jonesday.com

Mr Mark Thomas
Editor-in-Chief, uSpiked

By email: info@uspiked.com; ombudsman@uspiked.com

Dear Mr Thomas

The Cho Group Ltd, RMW Cho Group Pty Ltd, Next Generation PDT and Photosoft – publication of defamatory material

We act for The Cho Group Ltd and RMW Cho Group Pty Ltd.

We write on behalf of our clients in relation to the article '*Cancer Profiteers: Are You a Victim of This Cancer Scam?*', published on uSpiked's website on 14 May 2017, which you authored in your capacity as editor-in-chief of uSpiked.

In your article, you:

- (a) label Cho Group Ltd a '*predator*';
- (b) state that the Next Generation PDT and Photosoft treatments manufactured and promoted by both of our clients are akin to '*Barry Tannenbaum and American Bernie Madoff schemes*', with all of the fraudulent and exploitative connotations that such an analogy infers;
- (c) suggest that our clients are somehow seeking to abuse '*millions of desperate and vulnerable cancer patients*' by advocating for '*snake oil*' treatments which amount to a '*scam*'; and
- (d) encourage customers of our clients to stop dealing with our clients so they can avoid being '*victims*'.

AUI-930234480v1

ALKHOBAR • AMSTERDAM • ATLANTA • BEIJING • BOSTON • BRISBANE • BRUSSELS • CHICAGO • CLEVELAND • COLUMBUS • DALLAS
DUBAI • DÜSSELDORF • FRANKFURT • HONG KONG • HOUSTON • IRVINE • JEDDAH • LONDON • LOS ANGELES • MADRID
MEXICO CITY • MIAMI • MILAN • MOSCOW • MUNICH • NEW YORK • PARIS • PERTH • PITTSBURGH • RIYADH • SAN DIEGO
SAN FRANCISCO • SÃO PAULO • SHANGHAI • SILICON VALLEY • SINGAPORE • SYDNEY • TAIPEI • TOKYO • WASHINGTON

Your statements (both express and implied) are entirely unsubstantiated and lack any proper factual basis. They are clearly and blatantly defamatory and are calculated to cause significant detriment to our clients' businesses by deterring customers from dealing with our clients and undermining our clients' high regard and reputation in the market.

The publication of the article entitles our clients to seek an injunction and both general and aggravated damages against you and uSpiked in each jurisdiction in which the article has been accessed worldwide.

Our clients demand that you remove the article from uSpiked's website, and confirm to us in writing that you have done so, **by 8.00pm Australian Eastern Standard Time today.**

If you fail to remove the article by that time, we are instructed that our clients intend to immediately institute legal proceedings compelling you to do so.

While your removal of the article may limit the accumulation of any further damages, our clients reserve the right to commence proceedings against you and uSpiked for the damage that has already accrued as a result of the publication of the article and will continue to accrue until the article is removed.

Yours faithfully

Brett Heading
Partner
Jones Day



michael honsue cho



Sign in

[All](#)
[Images](#)
[Videos](#)
[News](#)
[Maps](#)
[More](#)
[Settings](#)
[Tools](#)

About 482 results (0.32 seconds)

ASX tells Invion to stop pursuing backdoor listing without consent ...
<https://stockhead.com.au/.../asx-tells-invion-to-stop-pursuing-backdoor-listing-without...>

Sep 4, 2017 - In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman Michael Honsue Cho is listed as their biggest ...

The Cho Group :: Company Profile
chogroup.com.au/company_profile.php

The Cho Group is a Hong Kong registered company with its head office ... Michael Honsue Cho is the Chairman and major shareholder of The Cho Group.

The Men of Fake Cancer Cure | uSpiked
<https://www.uspiked.com> › Justice › Governance

Jun 18, 2017 - The Cho Group through its chairman, Honsue Cho, claims to have ... Chairman Cho, who also goes by the name 'Michael', has taken great ...

We Shall Not Be Cowed | uSpiked
<https://www.uspiked.com> › Justice › Governance

May 20, 2017 - The Cho Group Ltd, which says its drug cures cancer, wants us to delete ... Michael Honsue Cho, the chairman and major shareholder of The ...

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page-1 ...
<https://hotcopper.com.au/threads/substantial-share-holding.3734160/>

Oct 5, 2017 - Michael Honsue Cho is the Chairman and major shareholder of The Cho Group. Other active shareholders/partners of The Cho Group include ...

Apology, page-1 13 Oct 2017

AGM notice, page-1 10 Oct 2017

More results from hotcopper.com.au

Michael Honsue Cho | Facebook
<https://en-gb.facebook.com/michaelhonsue.cho>

Michael Honsue Cho is on Facebook. Join Facebook to connect with Michael Honsue Cho and others you may know. Facebook gives people the power to share ...

[PDF] Jan 21, 2018 - Biotech Daily
www.biotechdaily.com.au/.../BD%20Biotech%20Daily%20Jan%2021a%202018%20S...

Jan 27, 2018 - HONSUE CHO, UNLIMITED INNOVATION TAKE 71% OF INVION. * OPOTHEA ... PHYLOGICA APPOINTS MICHAEL WILLIAMS DIRECTOR.

The Australian - IVX Profile
<https://markets.theaustralian.com.au/shares/IVX/invion-limited>

IVX OWNERS. Created with Highstock 1.3.0 51.2% 9.9% 5.2% 33.7%. Unlimited Innovation Group Limited, Polar Ventures Limited, Mr Honsue Cho, Other ...

Clinical Study : NGPDT For Advanced Non-small Cell Lung Cancer
www.nextgenerationpdt.com/.../clinical-study-ngpdt-for-advanced-...

Michael Honsue Cho NGPDT cancer center of Guangzhou friendship hospital 史葛·沃特广州友好医院 新一代光动力肿瘤治疗中心, Scott Waters NGPDT cancer ...

Images for michael honsue cho
[→ More images for michael honsue cho](#)
[Report Images](#)

3/14/2019

michael honsue cho - Google Search

Searches related to michael honsue cho

the cho group

ngpdt australia

1 2 3 4 5 6 7 8 9 10 Next

Australia 6000, Perth WA - From your Internet address - Use precise location - Learn more

Help Send feedback Privacy Terms



honsue cho



Sign in

All Images Videos Maps News More Settings Tools

About 883 results (0.37 seconds)

Did you mean: **honsu** cho

The Men of Fake Cancer Cure | uSpiked

<https://www.uspiked.com> › Justice › Governance ▼

Jun 18, 2017 - The Cho Group through its chairman, Honsue Cho, claims to have investments in advanced technologies, mining, ceramics industries, to name ...

The Cho Group :: Company Profile

chogroup.com.au/company_profile.php ▼

The Cho Group is a Hong Kong registered company with its head office ... Michael Honsue Cho is the Chairman and major shareholder of The Cho Group.

Cho Group |

chogroup.com.au/ ▼

Michael Honsue Cho is the Chairman and major shareholder of The Cho Group ... the Environmental and Humanitarian aspects of the Cho Group include:

ASX tells Invion to stop pursuing backdoor listing without consent ...

<https://stockhead.com.au/.../asx-tells-invion-to-stop-pursuing-backdoor-listing-without...> ▼

Sep 4, 2017 - In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman Michael Honsue Cho is listed as their biggest ...

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page-1 ...

<https://hotcopper.com.au/threads/substantial-share-holding.3734160/> ▼

Oct 5, 2017 - Honsue Cho. He has cho-wed up 15% in IVX. I think he lives in Kew in Melbourne so he know more than most of us, well me anyway living in ...

EXO/IVX, page-1 17 Sep 2018

Too good to be true!, page-1 ... 5 Apr 2018

Apology, page-1 13 Oct 2017

AGM notice, page-1 10 Oct 2017

More results from hotcopper.com.au

Invion Ltd's strategic alliance with Cho Group provides distribution ...

<https://www.proactiveinvestors.com.au/.../invion-s-strategic-alliance-with-cho-group-p...> ▼

Mar 2, 2018 - The Cho Group agreed to appoint Invion as exclusive distributor and licensee of the Photosoft technology in Australia and New Zealand for the ...

Images for honsue cho



→ More images for honsue cho

Report images

The Australian - IVX Profile

<https://markets.theaustralian.com.au/shares/IVX/invion-limited> ▼

IVX OWNERS. Created with Highstock 1.3.0 51.2% 9.9% 5.2% 33.7%. Unlimited Innovation Group Limited. Polar Ventures Limited. Mr Honsue Cho. Other ...

IVX Shareholder Activity - Top 20 Shareholders | afr.com

www.afr.com › Markets Data ▼

The Australian Financial Review reports the latest news from business, finance, investment and politics, updated in real time. It has a reputation for independent, ...

3/14/2019

honsue cho - Google Search

Honsue CHO Inventions, Patents and Patent Applications - Justia ...

<https://patents.justia.com/inventor/honsue-cho> ▼

USPTO patent applications submitted by and patents granted to Honsue CHO.

Searches related to honsue cho

ngpdt australia

the cho group

1 2 3 4 5 6 7 8 9 10 Next

Australia 6000, Perth WA - From your Internet address - Use precise location - Learn more

[Help](#) [Send feedback](#) [Privacy](#) [Terms](#)

https://www.google.com/search?ei=1O-JXMGeKtTfz7sPlvG_qAI&q=honsue+cho&oq=honsue+cho&gs_l=psy-ab.3..0i7i30j0i10i30.54304.54976..56406... 2/2



Michael honsue cho



Sign in

All Images News Videos Maps More Settings Tools

About 407 results (0.26 seconds)

We Shall Not Be Cowed | uSpiked

<https://www.uspiked.com> › Justice › Governance ▼

May 20, 2017 - The Cho Group Ltd, which says its drug cures cancer, wants us to delete ... **Michael Honsue Cho**, the chairman and major shareholder of The ...

The Men of Fake Cancer Cure | uSpiked

<https://www.uspiked.com> › Justice › Governance ▼

Jun 18, 2017 - The Cho Group through its chairman, **Honsue Cho**, claims to have ... Chairman **Cho**, who also goes by the name 'Michael', has taken great ...

The Cho Group :: Company Profile

chogroup.com.au/company_profile.php ▼

The Cho Group is a Hong Kong registered company with its head office ... **Michael Honsue Cho** is the Chairman and major shareholder of The Cho Group.

ASX tells Invion to stop pursuing backdoor listing without consent ...

<https://stockhead.com.au/.../asx-tells-invion-to-stop-pursuing-backdoor-listing-without...> ▼

Sep 4, 2017 - In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman **Michael Honsue Cho** is listed as their biggest ...

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page-1 ...

<https://hotcopper.com.au/threads/substantial-share-holding.3734160/> ▼

Oct 5, 2017 - **Michael Honsue Cho** is the Chairman and major shareholder of The Cho Group. Other active shareholders/partners of The Cho Group include ...

Apology, page-1

13 Oct 2017

AGM notice, page-1

10 Oct 2017

More results from hotcopper.com.au

Michael Honsue Cho | Facebook

<https://www.facebook.com/michaelhonsue.cho>

Michael Honsue Cho is on Facebook. Join Facebook to connect with **Michael Honsue Cho** and others you may know. Facebook gives people the power to share ...

Invion Ltd's strategic alliance with Cho Group provides distribution ...

<https://www.proactiveinvestors.com.au/.../invion-s-strategic-alliance-with-cho-group-p...> ▼

Mar 2, 2018 - The Cho Group agreed to appoint Invion as exclusive distributor and licensee of the Photosoft technology in Australia and New Zealand for the ...

PDF Jan 21, 2018 - Biotech Daily

www.biotechdaily.com.au/.../BD%20Biotech%20Daily%20Jan%2021a%202018%20S... ▼

Jan 27, 2018 - **HONSUE CHO**, UNLIMITED INNOVATION TAKE 71% OF INVION. * OPHEA ...
PHYLOGICA APPOINTS **MICHAEL WILLIAMS** DIRECTOR.

Clinical Study : NGPDT For Advanced Non-small Cell Lung Cancer

www.nextgenerationpdt.com/.../clinical-study-ngpdt-for-advanced-... ▼ Translate this page

Michael Honsue Cho NGPDT cancer center of Guangzhou friendship hospital 史基·沃特广州友好医院
新一代光动力肿瘤治疗中心. Scott Waters NGPDT cancer ...

Images for Michael honsue cho



→ More images for Michael honsue cho

Report images

3/14/2019

Michael honsue cho - Google Search

Searches related to Michael honsue cho

the cho group
ngpdt australia

1 2 3 4 5 6 7 8 9 10 Next

Hong Kong **Victoria, Australia** - From your search history - Use precise location - Learn more

Help Send feedback Privacy Terms

https://www.google.com/search?ei=UPCJXJDkGr7dz7sP59ut0AQ&q=Michael+honsue+cho&oq=Michael+honsue+cho&gs_l=psy-ab.12..0i30.25256.2... 2/2



honsue cho



Sign in

All Images Maps Videos News More Settings Tools

About 215 results (0.23 seconds)

The Men of Fake Cancer Cure | uSpiked

<https://www.uspiked.com> › Justice › Governance ▼

Jun 18, 2017 - The Cho Group through its chairman, **Honsue Cho**, claims to have investments in advanced technologies, mining, ceramics industries, to name ...

Cho Group |

chogroup.com.au/ ▼

Michael **Honsue Cho** is the Chairman and major shareholder of The Cho Group ... the Environmental and Humanitarian aspects of the Cho Group include:

The Cho Group :: Company Profile

chogroup.com.au/company_profile.php ▼

The Cho Group is a Hong Kong registered company with its head office ... Michael **Honsue Cho** is the Chairman and major shareholder of The Cho Group.

Images for honsue cho



→ More images for honsue cho

Report images

ASX tells Invion to stop pursuing backdoor listing without consent ...

<https://stockhead.com.au/.../asx-tells-invion-to-stop-pursuing-backdoor-listing-without...> ▼

Sep 4, 2017 - In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman Michael **Honsue Cho** is listed as their biggest ...

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page-1 ...

<https://hotcopper.com.au/threads/substantial-share-holding.3734160/> ▼

Oct 5, 2017 - **Honsue Cho**. He has cho-wed up 15% in IVX. I think he lives in Kew in Melbourne so he know more than most of us, well me anyway living in ...

EXO/IVX, page-1 17 Sep 2018

Too good to be true!, page-1 ... 5 Apr 2018

Apology, page-1 13 Oct 2017

AGM notice, page-1 10 Oct 2017

More results from hotcopper.com.au

Honsue CHO Inventions, Patents and Patent Applications - Justia ...

<https://patents.justia.com/inventor/honsue-cho> ▼

USPTO patent applications submitted by and patents granted to **Honsue CHO**.

Michael Honsue Cho | Facebook

<https://www.facebook.com/michaelhonsue.cho>

Michael **Honsue Cho** is on Facebook. Join Facebook to connect with Michael **Honsue Cho** and others you may know. Facebook gives people the power to share ...

Invion Ltd's strategic alliance with Cho Group provides distribution ...

<https://www.proactiveinvestors.com.au/.../invion-s-strategic-alliance-with-cho-group-p...> ▼

Mar 2, 2018 - The Cho Group agreed to appoint Invion as exclusive distributor and licensee of the Photosoft technology in Australia and New Zealand for the ...

#chogroup hashtag on Twitter

<https://twitter.com/hashtag/chogroup>

3/14/2019

honsue cho - Google Search

Thanks to @jessicakriegel for a fantastic session at this morning's New York #CHOGroup meeting, where she talked the dangers (and stupidity) of stereotyping ...

Searches related to honsue cho

ngpdt australia

the cho group

1 2 3 4 5 6 7 8 9 10 Next

Hong Kong **Victoria, Australia** - From your search history - Use precise location - Learn more

Help Send feedback Privacy Terms

https://www.google.com/search?ei=UPCJXJDkGr7dz7sP59ut0AQ&q=honsue+cho&oq=honsue+cho&gs_l=psy-ab.3..0i7112.0.0..4868...0.0..0.0.0.....0.... 2/2

3/14/2019

michael honsue cho - 国内版 Bing

 国内版 国际版
michael honsue cho

[Web](#) [Images](#) [Videos](#) [Academic](#) [Dict](#) [Maps](#)

 Try

Looks like you're searching in English.
Try our international version for better English language search results.

41 Results Any time ▾

We Shall Not Be Cowed | uSpiked

2017-5-20 · Michael Honsue Cho, the chairman and major shareholder of The Cho Group, appears to have many tentacles in business. He once invented a multi-layered wine barrel, which few winemakers bothered to buy. Cho and his companies have every right to view cancer patients as cash cows.
<https://uspiked.com/.../governance/2017/05/20/we-shall-not-be-cowed> ▼

Cho Group

Michael Honsue Cho is the Chairman and major shareholder of The Cho Group. OUR PORTFOLIO. Some of our projects which exemplify the Environmental and Humanitarian aspects of the Cho Group include: read more. INVESTMENT OPPORTUNITY.
chogroup.com.au ▼

Clinical Study : NGPDT For Advanced Non-small ... Translate this page

Michael Honsue Cho NGPDT cancer center of Guangzhou friendship hospital 史基·沃特 广州友好医院新
 一代光动力肿瘤治疗中心 Scott Waters NGPDT cancer center of ...
www.nextgenerationpdt.com/clinical-studies/clinical... ▼

The Men of Fake Cancer Cure | uSpiked



2017-5-19 · The Men of Fake Cancer Cure the audacity of cancer profiteers. ...
 Honsue Cho. Age: Unknown Nationality: Chinese Profession: A serial inventor
 and Chairman and major shareholder of The Cho Group. ... Chairman Cho, who
 also goes by the name 'Michael...
<https://www.uspiked.com/.../2017/05/18/the-men-of-fake-cancer-cure> ▼

ASX tells Invion to stop pursuing backdoor listing without ...

Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 per cent of company. The ASX is getting particularly hot under the collar over Chinese companies listing in Australia, which have a reputation for not following the rules.
<https://stockhead.com.au/health/asx-tells-invion-to-stop-pursuing...> ▼

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page ...

Honsue Cho. He has cho-wed up 15% in IVX. I think he lives in Kew in Melbourne so he know more than most of us, well me anyway living in the western... Latest Posts. Forums. Created with Sketch. ...
<https://photocopper.co.nz/threads/substantial-share-holding.3734160> ▼

Synthesis and application of chlorin e6 zn-complex ...

Author: CHO HONSUE. Synthesis and application of chlorin e6 zn-complex. PAT - HK1084290
europepmc.org/patents/PAT/HK1084290 ▼

Biotech Daily

2018-2-21 · * honsue cho, unlimited innovation take 71% of invion * opthea starts opt-302 trial for diabetic macular oedema * micro x releases 28m escrow shares ... * michael abolakian, hishenk take 8% of kazia * invitroque releases 349m shares from voluntary escrow
www.biotechdaily.com.au/media/backissues/2018/01-Jan/BD-Biotech...

DIHYDROPORPHINE E6 ZINC COMPLEXES AS ...

Dihydroporphine E6 zinc complexes as photosensitizer, their preparation and their use. The method for preparing the said zinc complexes comprises the following steps: adding dihydroporphine E6 to sodium hydrogen carbonate aqueous solution, dissolving polyvinylpyrrolidone in de-ionized water, adding the obtained solution to dihydroporphine E6 solution, slow stirring under 40 DEG C to obtain ...
europepmc.org/patents/PAT/WO2007095828 ▼

The Australian - IVX Profile

Michael Roddan. ASIC says bank failed to make reasonable inquiries over limit required by customers. ANZ accused of rigging rate 19:28 4th Mar. ... Mr Honsue Cho. Other. IVX MANAGEMENT. Name Title; Melanie Farris: Company Secretary: Disclaimer. IVX BOARD. Name Title; Dr Gregory (Greg) Collier:
<https://markets.theaustralian.com.au/shares/IVX> ▼

Didn't find what you want?

Try our international version for better English language search results.

1 2 3 4 5 >

3/14/2019

honsue cho - 国内版 Bing



Web Images Videos Academic Dict Maps

Try

Looks like you're searching in English.
Try our international version for better English language search results.

1,290 Results Any time

HONSUE CHO 深圳优立视觉科技有限公... Translate this page

2016-6-23 · 天眼查为您提供HONSUE CHO个人信用信息查询、相关企业信息查询、股东法人查询、HONSUE CHO深圳优立视觉科技有限公司信息查询等个人信息查询服务 ...
<https://www.tianyancha.com/human/1751472264-c2374613867#>

Honsue CHO Inventions, Patents and Patent Applications ...

Honsue CHO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
patents.justia.com Justia

We Shall Not Be Cowed | uSpiked

2017-5-20 · Michael Honsue Cho, the chairman and major shareholder of The Cho Group, appears to have many tentacles in business. He once invented a multi-layered wine barrel, which few winemakers bothered to buy. Cho and his companies have every right to view cancer patients as cash cows.
<https://us spiked.com/.../governance/2017/05/20/we-shall-not-be-cowed>

ASX tells invion to stop pursuing backdoor listing without ...

Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 per cent of company. The ASX is getting particularly hot under the collar over Chinese companies listing in Australia, which have a reputation for not following the rules.
<https://stockhead.com.au/health/asx-tells-invion-to-stop-pursuing...>

Cho Group

Michael Honsue Cho is the Chairman and major shareholder of The Cho Group. OUR PORTFOLIO. Some of our projects which exemplify the Environmental and Humanitarian aspects of the Cho Group Include: read more. INVESTMENT OPPORTUNITY.
chogroup.com.au

Legal action against Mr Mark Thomas - chogroup.com.au

Melbourne, Australia – 7 November 2018: The Cho Group wishes to advise that its founder and chairman, Michael Honsue Cho, has commenced legal proceedings in Australia against Mr Mark Thomas, the editor-in-chief of an online gossip site.
chogroup.com.au/cho-group/legal-action-against-mr-mark-thomas

Biotech Daily

2017-10-11 · Cho Group chairman Honsue Cho has become a substantial shareholder in Invion with 218,894,000 shares, or 15.03 percent of the company. The Melbourne-based Mr Cho said he acquired 33,333,333 shares for \$100,000 on April 21, and 185,560,667 shares for \$556,682 on June 8, 2017 all at 0.3 cents a share.
[www.biotechdaily.com.au/media/backissues/2017/10/OctBD Biotech...](http://www.biotechdaily.com.au/media/backissues/2017/10/OctBD%20Biotech...)

Clinical Study : NGPDT For Advanced Non-small ... Translate this page

Michael Honsue Cho NGPDT cancer center of Guangzhou friendship hospital 史葛·沃特 广州友好医院新一代光动力肿瘤治疗中心 Scott Waters NGPDT cancer center of ...
www.nextgenerationpdt.com/clinical-studies/clinical...

深圳优立视觉科技有限公司-张雪兵【工商信息-电话 ... Translate this page

2019-1-21 · Honsue Cho 他关联 2 家公司 > 董事 5 张雪兵 他关联 20 家公司 > 董事长 6 张雪兵 他关联 20 家公司 > 总经理 公司公示 6 股东及出资信息 该信息由该 ...
https://www.qichacha.com/firm_5fab5dbfda4e43a19e3e978b...

US20150315202A1 - Chlorin derivative useful in ...

Cited by: 1 Author: Honsue Cho
 Publish Year: 2015

US20150315202A1 - Chlorin derivative useful in photodynamic therapy and diagnosis - Google Patents
 ... Honsue CHO Current Assignee (The listed assignees may be inaccurate. ... Chlorin derivative useful in photodynamic therapy and diagnosis Country Status (12) Country Link; US (1) US20150315202A1 (en) ...
<https://patents.google.com/patent/US20150315202A1/en>

Didn't find what you want?

Try our international version for better English language search results.

1 2 3 4 5 >



michael honsue cho



Sign in

1

All Images Videos Maps News | My saves

Make Bing your

41 Results Date Language Region

Cho Group

chogroup.com.au

Welcome to the Cho Group. Michael Honsue Cho is the Chairman and major shareholder of The Cho Group

We Shall Not Be Cowed | uSpiked

uspike.com › Justice › Governance

Michael Honsue Cho, the chairman and major shareholder of The Cho Group, appears to have many tentacles in business. He once invented a multi-layered wine barrel, ...

Legal action against Mr Mark Thomas - chogroup.com.au

chogroup.com.au/cho-group/legal-action-against-mr-mark-thomas

Defamation action against the editor of gossip website has commenced; Law firm Jones Day has been appointed as solicitors for Michael Honsue Cho

The Men of Fake Cancer Cure | uSpiked

www.uspike.com › Justice › Governance

The Cho Group through its chairman, Honsue Cho, claims to have investments in advanced technologies, mining, ceramics industries, to name a few. The patent documents found by our team suggest Cho is a serial inventor with at least three patents.

ASX tells Invion to stop pursuing backdoor listing without ...

https://stockhead.com.au/health/asx-tells-invion-to-stop-pursuing...

In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 per cent of company. Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 ...

INVION LIMITED (ASX:IVX) - Substantial Share Holding, page ...

https://hotcopper.co.nz/threads/substantial-share-holding.3734160

Honsue Cho. He has cho-wed up 15% in IVX. I think he lives in Kew in Melbourne so he know more than most of us, well me anyway living in the western...

The Australian - IVX Profile

https://markets.theaustralian.com.au/shares/IVX

Stock Ownership of a corporation indicated by shares, which represent a piece of the corporation's assets and earnings. Earnings per share (EPS) A company's profit divided by ...

Clinical Study: NGPDT For Advanced Non-small Cell ...

www.nextgenerationpdt.com/clinical-studies/clinical-study-ngpdt...

Michael Honsue Cho NGPDT cancer center of Guangzhou friendship hospital 史基·沃特 广州友好医院新一代光动力肿瘤治疗中心 Scott Waters NGPDT cancer center of Guangzhou friendship hospital 王丹丹 广州友好医院新一代光动力肿瘤治疗中心 Wang Dandan NGPDT cancer center of Guangzhou friendship hospital 阮晶晶 广州友好医院新一代光动力肿瘤 ...

Biotech Daily

www.biotechdaily.com.au/media/backissues/2018/01 Jan/BD Biotech... PDF file

* honsue cho, unlimited Innovation take 71% of Invion * opthea starts opt-302 trial for diabetic macular oedema * micro x releases 28m escrow shares * mgc responds to asx \$1m varm cosmo payment query * director urs wetstein transfers 650,000 g medical shares * phylogica appoints michael williams director * federal government legalizes medical marijuana exports * mgc launches marijuana derma ...

Synthesis and application of chlorin e6 zn-complex ...

europemc.org/patents/PAT/HK1084290

cho honsue, Or filter your current search OVCHINNIKOV ALEXANDER, Find all citations by this author (default). Or filter your current search MURPHY MATT CHO HONSUE

1 2 3 4 5 >

3/14/2019

honsue cho - Bing



honsue cho



Sign in

All

Images

Videos

Maps

News

My saves

Make Bing your

10,100 Results

Date ▼

Language ▼

Region ▼

Cho Group

chogroup.com.au

Welcome to the Cho Group. Michael Honsue Cho is the Chairman and major shareholder of The Cho Group

ASX tells Invion to stop pursuing backdoor listing without ...

<https://stockhead.com.au/health/asx-tells-invion-to-stop-pursuing...>

In April Cho Group bought 218.9 million new shares in Invion, for \$656,682. Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 per cent of company. Cho Group chairman Michael Honsue Cho is listed as their biggest shareholder with about 15 per cent of company.

We Shall Not Be Cowed | uSpiked

uspoiked.com › Justice › Governance

Michael Honsue Cho, the chairman and major shareholder of The Cho Group, appears to have many tentacles in business. He once invented a multi-layered wine barrel , ...

The Men of Fake Cancer Cure | uSpiked

www.uspoiked.com › Justice › Governance

Honsue Cho. Age: Unknown Nationality: Chinese Profession: A serial inventor and Chairman and major shareholder of The Cho Group. At Suite 3A08, 4/F, Fuli Tianhe Commercial Building in Tian He District, Guangzhou Province, one might find The Cho Group head office.

Honsue CHO Inventions, Patents and Patent Applications ...

<https://patents.justia.com/inventor/honsue-cho>

Honsue CHO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Biotech Daily

www.biotechdaily.com.au/media/backissues/2017/10/Oct/BD%20Biotech... PDF file

Cho Group chairman Honsue Cho has become a substantial shareholder in Invion with 218,894,000 shares, or 15.03 percent of the company. The Melbourne-based Mr Cho said he acquired 33,333,333 shares for \$100,000 on April

Invion Limited (ASX:IVX) - Shares, Dividends & News ...

www.investsmart.com.au › Research › Shares

17/01/2019 · Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein.

Website: <http://www.inviongroup.com> **GICS Sub-Industry:** Pharmaceuticals
Name: Invion Limited **Stock Code:** IVX

Stockhead - ASX Small Caps News - Australian Stocks & ASX ...

<https://stockhead.com.au>

Stockhead is providing factual information where there is a reasonable likelihood of doubt. The information is not intended to imply any recommendation or opinion about a financial product.

Seung-Hui Cho - Wikipedia



https://en.wikipedia.org/wiki/Seung-Hui_Cho

Seung-Hui Cho (조승희 in Korean, properly Cho Seung-Hui; January 18, 1984 – April 16, 2007) was a South Korean-born spree killer and mass murderer who killed 32 people and wounded 17 others armed with two semi-automatic pistols on April 16, 2007, at the ...

Early life and education · Cho at Virginia Tech · Psychiatric evaluation

Những điểm nổi bật trong sách Giô-suê — THƯ VIỆN TRỰC ...

<https://wol.jw.org/vi/wol/d/r47/p-vt/2004882>

Không có video nào cho phần được chọn. Có lỗi trong việc tải video.

1 2 3 4 5 >